google.com, pub-9294893883853578, DIRECT, f08c47fec0942fa0 Coronavirus Vaccine Status, Latest Updates | Covid 19 Vaccine

Coronavirus Vaccine Status, Latest Updates | Covid 19 Vaccine

Researchers worldwide are working around the clock to find a COVID19 vaccine.

covid 19 vaccine

Vaccines typically require years of research and testing before reaching the clinic, but scientists are racing to produce a safe and effective coronavirus vaccine by next year. Researchers are testing 49 vaccines in clinical trials on humans, and at least 88 preclinical vaccines are under active investigation in animals.

Here is the list of vaccines that has reached phase three and beyond.

Novavax

An American vaccine development company.

Status:

The company is in the Phase III trial of making NVX-CoV2373-Covid Vaccine in the United Kingdom, which will evaluate the vaccine in up to 10,000 people, both with and without underlying conditions. 

Johnson & Johnson

An American multinational corporation.

Status: 

Johnson & Johnson announced the launch of phase III of JNJ-78436735-COVID 19 Vaccine on September 23. 60,000 adults from a variety of countries are ensemble for a trial to evaluate the safety of the vaccine—and how well it works. The trial will include “significant representation” from older populations and those with underlying conditions that make them more susceptible to COVID-19.


Sinopharm

China’s state-run pharmaceutical company

Status:

Sinoparm is filing its application to China’s regulatory commission for approval of the vaccine, which could arrive sometime in September. The story also notes that hundreds of thousands of Chinese civilians have already been vaccinated under the government’s emergency-use approval. China began to innoculate medical workers and other high-risk groups with the Sinopharm trial vaccines in July, making it the first experimental vaccine available to civilians beyond clinical volunteers.


Pfizer

A pharmaceutical company based in New York.

Status: 

Pfizer and BioNTech launched the BNT162b2-Covid vaccine's trial that combines phases two and three by enrolling a diverse population in areas with significant SARS-CoV-2 transmission. It has expanded the trial to include 44,000 people across multiple countries. The vaccine is aiming to seek regulatory review before the end of the year and hopes to supply 1.3 billion doses by the end of 2021. 


University of Oxford

The U.K. university.

Status:

Preliminary results from this candidate’s first two clinical trial phases revealed that the ChAdOx1nCoV-19-Covid vaccine had triggered a strong immune response including increased antibodies and responses from T-cells with only minor side effects such as fatigue and headache. It is in phase three of clinical trials, aiming to recruit up to 50,000 volunteers in Brazil, the United Kingdom, the United States, and South Africa.


Sinovac

A Chinese biopharmaceutical company

Status: 

Brazil’s regulatory agency granted CoronaVac-Covid vaccine candidate approval to move ahead to phase three, as it continues to monitor the results of phase two clinical trials. Preliminary results in macaque monkey revealed that the vaccine produced antibodies that neutralized 10 strains of SARS-CoV-2. Phase three will recruit nearly 9,000 healthcare professionals in Brazil. Sinovac will also conduct phase three trials in Indonesia and Bangladesh.


CanSino Biologics

A Chinese biopharmaceutical company.

Status

Ad5-nCoV-Covid Vaccine is in the Phase III trial. The Chinese government has approved the vaccine for military use only, for a period of one year. On August 15, Russian biopharmaceutical company Petrovax announced it had launched the first phase three clinical trial of Ad5-nCoV.


Moderna Therapeutics

A Massachusetts-based biotech company based in America.

Status: 

Moderna announced is in the third phase of its clinical trials of the mRNA-1273-Covid vaccine, even as it continues to monitor phase two results. Phase three will test the vaccine in 30,000 U.S. participants; Moderna says it is on track to deliver at least 500 million doses per year beginning in 2021, thanks in part to the deal it has struck with Swiss manufacturer Lonza that will allow it to manufacture up to one billion doses a year.

0/Post a Review/Reviews

Please do not add any spam link in the comment box

Previous Post Next Post